Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
PURPOSE The risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well described. We characterized GI adverse events in patients with underlying IBD who received immune checkpoint inhibitors. PATIENTS AND METHO...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 语言: | 英语 |
| 出版: |
2019
|
| 在线阅读: | https://doi.org/10.1200/jco.19.01674 |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|